Research Analysts Offer Predictions for Vertex Pharmaceuticals Incorporated’s Q2 2025 Earnings (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Equities researchers at Zacks Research increased their Q2 2025 EPS estimates for shares of Vertex Pharmaceuticals in a research report issued on Tuesday, September 24th. Zacks Research analyst R. Department now expects that the pharmaceutical company will post earnings of $4.04 per share for the quarter, up from their previous forecast of $4.00. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is ($2.14) per share. Zacks Research also issued estimates for Vertex Pharmaceuticals’ Q3 2025 earnings at $3.91 EPS, Q4 2025 earnings at $3.96 EPS, FY2025 earnings at $15.71 EPS and Q1 2026 earnings at $4.10 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Thursday, August 1st. The pharmaceutical company reported ($12.83) EPS for the quarter, missing the consensus estimate of ($12.54) by ($0.29). The company had revenue of $2.65 billion during the quarter, compared to the consensus estimate of $2.66 billion. Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. The company’s revenue was up 6.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.53 earnings per share.

Other equities research analysts have also recently issued reports about the stock. TD Cowen boosted their price objective on shares of Vertex Pharmaceuticals from $450.00 to $500.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Guggenheim boosted their price target on shares of Vertex Pharmaceuticals from $450.00 to $558.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Barclays cut shares of Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $472.00 to $509.00 in a research report on Monday, August 5th. Oppenheimer boosted their price target on shares of Vertex Pharmaceuticals from $500.00 to $550.00 and gave the stock an “outperform” rating in a research report on Monday, August 5th. Finally, Wells Fargo & Company boosted their price target on shares of Vertex Pharmaceuticals from $540.00 to $555.00 and gave the stock an “overweight” rating in a research report on Monday, June 24th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $486.36.

Vertex Pharmaceuticals Trading Down 0.1 %

VRTX opened at $462.88 on Friday. The stock has a market capitalization of $119.47 billion, a P/E ratio of 30.15 and a beta of 0.40. Vertex Pharmaceuticals has a 12 month low of $341.85 and a 12 month high of $510.64. The firm’s fifty day simple moving average is $480.50 and its 200 day simple moving average is $453.23. The company has a current ratio of 2.52, a quick ratio of 2.26 and a debt-to-equity ratio of 0.02.

Insider Activity at Vertex Pharmaceuticals

In other news, CEO Reshma Kewalramani sold 15,202 shares of the stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $497.00, for a total transaction of $7,555,394.00. Following the completion of the sale, the chief executive officer now directly owns 106,172 shares in the company, valued at $52,767,484. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, CEO Reshma Kewalramani sold 15,202 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $497.00, for a total transaction of $7,555,394.00. Following the completion of the transaction, the chief executive officer now directly owns 106,172 shares in the company, valued at $52,767,484. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $476.75, for a total transaction of $1,086,990.00. Following the transaction, the chief marketing officer now owns 23,259 shares of the company’s stock, valued at $11,088,728.25. The disclosure for this sale can be found here. Insiders sold a total of 31,767 shares of company stock valued at $15,768,284 in the last quarter. Insiders own 0.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in VRTX. Aveo Capital Partners LLC lifted its position in shares of Vertex Pharmaceuticals by 77.3% during the fourth quarter. Aveo Capital Partners LLC now owns 1,076 shares of the pharmaceutical company’s stock valued at $438,000 after purchasing an additional 469 shares in the last quarter. Gryphon Financial Partners LLC raised its position in Vertex Pharmaceuticals by 26.5% in the fourth quarter. Gryphon Financial Partners LLC now owns 1,978 shares of the pharmaceutical company’s stock worth $805,000 after acquiring an additional 414 shares during the period. Quest Partners LLC bought a new stake in Vertex Pharmaceuticals in the fourth quarter worth about $33,000. Stifel Financial Corp raised its position in Vertex Pharmaceuticals by 12.7% in the fourth quarter. Stifel Financial Corp now owns 99,607 shares of the pharmaceutical company’s stock worth $40,529,000 after acquiring an additional 11,191 shares during the period. Finally, Focus Financial Network Inc. ADV bought a new stake in Vertex Pharmaceuticals in the fourth quarter worth about $245,000. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.